IQV Options Skew Flags Caution Into Monday's Print

Options traders are leaning bearish on IQV ahead of Q2 results due July 28. The put-call ratio sits at 1.16 — nearly two standard deviations above its 20-day mean of 0.92. That's the clearest signal in the current data.

The stock gained 4.4% on July 23 and is up 23.5% over the past month. Yet the options market is hedging hard rather than chasing the move.

Puts Dominating Into Earnings

The PCR of 1.16 compares to a 20-day mean of 0.92 and a standard deviation of 0.125. The z-score of 1.97 puts current put positioning near the top of the recent range. The 52-week PCR high is 2.65, so there is room for further skew — but the direction is clear. Traders are buying protection.

The previous earnings print supports some caution. Q1 results on May 5 moved the stock 9.6% in a single day. The July 22 result produced a 2.8% move. History shows this name can gap meaningfully, in either direction.

Short Sellers Step Back

Short interest tells a different story. SI has fallen 14% over the past month to 2.66% of free float — a multi-month low. That is a low absolute level and not the primary driver here. What is notable is the divergence: short sellers are covering, but options traders are buying puts. Those are not the same actors making the same bet.

The cost to borrow rose 56% week-on-week to 0.70%. That sounds sharp, but availability remains exceptionally loose at 4,908% — more than 123 million shares available to borrow against current short positions. The CTB move reflects a small change in a very uncrowded borrow market. It is not a squeeze signal.

Analyst Backdrop

The analyst setup was covered in depth in ORTEX's July 19 earnings preview. In brief: Mizuho raised its target to $230 and Baird to $249, both maintaining Outperform. Morgan Stanley downgraded to Equal-Weight in mid-June with a $200 target. The consensus mean sits at $232 — roughly 12% above current levels. The Street is split, which is consistent with the options market hedging rather than positioning directionally.

The ORTEX short score has drifted lower, from 35.7 on July 9 to 34.1 on July 22. The score has been declining steadily. That reflects the unwinding of short positions rather than any new bullish signal.

Data Summary

• PCR: 1.16, z-score 1.97 vs 20-day mean of 0.92
• Short interest: 2.66% of free float, down 14% over 30 days
• Cost to borrow: 0.70%, up 56% week-on-week
• Availability: 4,908% — lending market remains very loose
• Stock price: $207.32, +4.4% on July 23, +23.5% over one month
• Next earnings: July 28
• Consensus price target: $232 (432 institutional holders)

What to watch: Whether the PCR holds elevated or normalises into the July 28 print — and whether the Q2 result resolves the growth deceleration debate that has divided the Street since Morgan Stanley's June downgrade.